Screener
Regenxbio RGNX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income from licensing | 17 | 21 | 33 | 46 |
| Investment income | 1,222 | 3,379 | 3,225 | 5,880 |
| Interest expense | (7,793) | (10,993) | (16,501) | (19,563) |
| Total other income (expense) | (6,554) | (7,593) | (13,243) | (13,637) |
| Net income (loss) | $22,709 | $(70,871) | $(67,342) | $(64,788) |
| Other Comprehensive Income (Loss) | ||||
| Unrealized gain (loss) on available-for-sale securities, net | (5) | 12 | (188) | (9) |
| Total other comprehensive income (loss) | (5) | 12 | (188) | (9) |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's other income (expense)?
- Regenxbio (RGNX) reported other income (expense) of -$6.55M in Q2 2026.
- How has Regenxbio's other income (expense) changed year-over-year?
- Regenxbio's other income (expense) increased by 13.7% year-over-year, from -$7.59M to -$6.55M.
- What is the long-term trend for Regenxbio's other income (expense)?
- Over 4 years (2021 to 2025), Regenxbio's other income (expense) has grown at a 14.9% compound annual growth rate (CAGR), from -$18.73M to -$32.68M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Regenxbio's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude